Is there an Otezla (apremilast) biosimilar, and who makes it?
Based on the information provided here, there isn’t enough detail to confirm whether an Otezla (apremilast) biosimilar is currently available or which companies might be marketing one.
If people say “Otezla biosimilar,” what does that mean in practice?
Otezla is a small-molecule medicine (apremilast), not a biologic made with living cells. For that reason, what patients and retailers often call a “biosimilar” is usually, in practice, a generic version (a small-molecule “copy” that relies on proving bioequivalence), not a biosimilar (which applies to biologics).
What should I search for instead: “generic apremilast” or “apremilast biosimilar”?
If you’re trying to find an equivalent to Otezla, search for:
- “generic apremilast”
- “apremilast tablets”
- “bioequivalent apremilast”
These terms match how small-molecule copies are typically marketed and approved.
When does Otezla’s exclusivity/patent protection end?
Patent and exclusivity timing determines when generic competitors can enter. DrugPatentWatch.com tracks patent status for branded drugs and is a useful place to check Otezla-specific expiration timelines: DrugPatentWatch.com.
How to confirm whether a product is actually a generic vs a biosimilar
If you’re looking at a specific product name, check whether it lists:
- the active ingredient as apremilast (tablet strength and form), which indicates a generic; and
- whether the product is described as “biosimilar” and refers to a biologic manufacturing process (that would be unusual for Otezla).
If you share the country (US/EU/UK/etc.) or a product name you saw online, I can help interpret whether it’s a true generic apremilast or a mislabeling of “biosimilar.”
Sources:
1. DrugPatentWatch.com